
HilleVax Inc (HLVX) Stock Forecast & Price Target
HilleVax Inc (HLVX) Analyst Ratings
Bulls say
HilleVax Inc., as a clinical-stage biopharmaceutical company, is advancing its promising vaccine candidate HIL-214, which has demonstrated exceptional immunogenicity, achieving a geometric mean fold rise greater than 18-fold in pan-Ig antibodies and impressive seroresponse rates of 99.0% and 86.9% for norovirus genotypes GI.1 and GII.4, respectively. The potential for widespread vaccination against norovirus, particularly in high-burden populations such as young children and older adults, supports a compelling market opportunity due to the significant healthcare costs associated with norovirus-induced acute gastroenteritis. Furthermore, with HilleVax remaining well-capitalized and actively exploring development options for both HIL-214 and its newly licensed candidate HIL-216, there exists a strong foundation for future growth and value creation in the biopharmaceutical sector.
Bears say
HilleVax Inc. faces significant challenges following disappointing top-line data from the Phase 2b NEST-IN1 trial, which led to the discontinuation of development for its HIL-214 norovirus vaccine candidate intended for infants. The company's reported net loss of $40.7 million, or $0.83 per share for Q2 2024, raises concerns regarding its financial sustainability, further compounded by a substantial workforce reduction of approximately 40% aimed at cutting operating expenses. The risks associated with the future development of its vaccine candidates, including failure to secure necessary capital and achieve projected revenue estimates, contribute to a negative outlook on the stock's potential performance.
This aggregate rating is based on analysts' research of HilleVax Inc and is not a guaranteed prediction by Public.com or investment advice.
HilleVax Inc (HLVX) Analyst Forecast & Price Prediction
Start investing in HilleVax Inc (HLVX)
Order type
Buy in
Order amount
Est. shares
0 shares